Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-18, Stock:NVS, The news for the past five days is as follows:
2019-04-11: NEWS1: Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon.NEWS2: Biotechnology Market on a Tear: 5 ETFs in Spotlight.NEWS3: Biotechnology Market on a Tear: 5 ETFs in Spotlight.NEWS4: Top Research Reports for McDonald's, Enterprise Products & Charles Schwab.NEWS5: Top Research Reports for McDonald's, Enterprise Products & Charles Schwab.NEWS6: Biotechnology Market on a Tear: 5 ETFs in Spotlight.NEWS7: Top Research Reports for McDonald's, Enterprise Products & Charles Schwab.NEWS8: Intercept Reports Additional Positive Data From NASH Study.NEWS9: Intercept Reports Additional Positive Data From NASH Study.NEWS10: Intercept Reports Additional Positive Data From NASH Study.NEWS11: Health Care Sector Update for 04/11/2019: AVGR, AUTL, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS12: Health Care Sector Update for 04/11/2019: AVGR, AUTL, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS13: Here’s the Real Problem with Altria Overpaying for CRON Stock.
2019-04-12: NEWS1: Ophthotech Gets Rights to Gene Therapy for BEST Disease.NEWS2: Ophthotech Gets Rights to Gene Therapy for BEST Disease.NEWS3: Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal.NEWS4: Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal.NEWS5: Ophthotech Gets Rights to Gene Therapy for BEST Disease.NEWS6: Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon.NEWS7: Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon.
2019-04-15: NEWS1: Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran.NEWS2: Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran.NEWS3: Alcon Stock Is Back. The Eye-care Company Deserves a Long, Hard Look..
2019-04-16: NEWS1: Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran.NEWS2: Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales.NEWS3: Allergan Falls as Supreme Court Dismisses Restasis Litigation.NEWS4: Allergan Falls as Supreme Court Dismisses Restasis Litigation.NEWS5: Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA.NEWS6: Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA.NEWS7: Marijuana ETF Down 9% in Past Month: Time to Enter the Space?.NEWS8: Allergan Falls as Supreme Court Dismisses Restasis Litigation.NEWS9: Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA.NEWS10: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives.
2019-04-17: NEWS1: Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted.NEWS2: Health Care Sector Update for 04/17/2019: IONS,NVS,MASI,TXMD,ONCS.NEWS3: Health Care Sector Update for 04/17/2019: IONS,NVS,MASI,TXMD,ONCS.NEWS4: Here's Why Ionis Pharmaceuticals Slumped Today.NEWS5: Here's Why Ionis Pharmaceuticals Slumped Today.NEWS6: Here&apos;s Why Ionis Pharmaceuticals Slumped Today.NEWS7: Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted.NEWS8: Marijuana ETF Down 9% in Past Month: Time to Enter the Space?.NEWS9: Marijuana ETF Down 9% in Past Month: Time to Enter the Space?.NEWS10: The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO.NEWS11: Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales.NEWS12: Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales.NEWS13: Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran.NEWS14: Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran.

Answer: Decrease